Related Experiment Video
Updated: May 3, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
12.7K
Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization
J Kevin Hicks, Jesse J Swen, Andrea Gaedigk1
1Clinical Pharmacology & Therapeutic Innovation, Children's Mercy Hospital, 2401 Gillham Rd, Kansas City, MO 64108, USA. agaedigk@cmh.edu.
Current Drug Metabolism
|February 15, 2014
Summary
Understanding cytochrome P450 2D6 (CYP2D6) genetic variations is crucial for personalized medicine. This review highlights challenges in CYP2D6 genotyping and proposes a standardized activity score system for accurate metabolic status assignment.
Area of Science:
- Pharmacogenomics
- Clinical Chemistry
- Molecular Biology
Background:
- The cytochrome P450 2D6 (CYP2D6) enzyme metabolizes ~25% of clinical drugs.
- CYP2D6 gene variations significantly impact drug response due to altered metabolic activity.
- Predicting individual metabolic status is key for optimizing drug therapy and dosage.
Purpose of the Study:
- To review the complexities of CYP2D6 genotyping and phenotype classification.
- To identify challenges in current CYP2D6 genotype interpretation and phenotype assignment.
- To advocate for a standardized system for CYP2D6 phenotype determination.
Main Methods:
- Review of current literature on CYP2D6 gene polymorphism and its clinical implications.
- Analysis of existing methodologies for CYP2D6 genotyping and phenotype assignment.
- Proposal of an activity score system for a continuum of metabolic activity.
Main Results:
- CYP2D6 genotyping is the preferred method for predicting metabolic status.
- Significant variability exists in genetic variants interrogated and interpretation across laboratories.
- Lack of standardization in translating genotype to phenotype leads to inconsistent clinical recommendations.
Conclusions:
- A universally accepted system for CYP2D6 phenotype assignment is needed for consistency.
- The proposed activity score system offers a more precise and actionable approach to metabolic status.
- Standardization will improve the clinical utility of CYP2D6 genotyping in personalized medicine.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94